Schizoaffective disorder is a chronic mental health condition characterized by the symptoms of schizophrenia, such as visual or auditory hallucinations, delusions, self-harm, impulsivity, and emotional dysregulation.
Patients affected with this disorder are often misdiagnosed with bipolar disorder or Schizophrenia. Schizoaffective disorder is less studied, and treatment interventions are often referred to for these disorders.
Epidemiology
Schizoaffective disorder is rare, with an estimated lifetime prevalence rate of 0.3%. Men and women are affected by this disorder at the same rate. According to recent evidence, cases of this disorder develop between the age of 25 and 35.
Inpatient admissions of schizoaffective disorder are due to psychosis and are estimated to be about 10% to 30%. There are no large-scale studies on the epidemiology, incidence, and prevalence of the schizoaffective disorder.
Anatomy
Pathophysiology
The specific pathophysiology of schizoaffective disorder is unknown. Some studies suggest abnormalities of serotonin, dopamine and norepinephrine have a role.
White matter alterations in several brain areas, including the left temporal gyrus, right lentiform nucleus, and right precuneus, have also been linked to schizoaffective disorder and schizophrenia.
Researchers discovered diminished hippocampus volume and deformations of the medial and lateral thalamic regions in schizoaffective disorder patients.
Etiology
There have been no definitive studies on the disorder’s cause. According to various research, up to 50% of individuals with schizophrenia have comorbid depression.
Both mood disorders and schizophrenia have heterogeneous pathogenesis that includes a variety of risk factors such as genetics, social factors, trauma, and stress. Stressful events and trauma usually trigger the disorder’s symptoms or onset.
To differentiate schizophrenia and schizoaffective disorder, an individual should have only psychomotor symptoms such as auditory or visual hallucinations for at least two weeks.
Genetics
First-degree relatives have a higher risk of developing schizoaffective disorder. Individuals with a family history of bipolar disorder and schizophrenia are also at a higher risk of being affected.
Prognostic Factors
Since the diagnostic criteria for schizoaffective disorder change periodically, prognosis studies have been challenging to conduct.
The estimated prognosis in individuals with psychotic disorder is about 50%. Schizoaffective disorder has various consequences on social functioning and daily activities if left untreated, like unemployment, depression, and reduced ability to care for self.
The prime reason for mortality is suicide; about 5% of patients with schizoaffective disorder commit suicide.
Clinical History
Physical Examination
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
Medication
Future Trends
Media Gallary
References
https://www.ncbi.nlm.nih.gov/books/NBK541012/
News
Rare Uterine Lipoma Diagnosed Post-Surgery: Case Report
Posted on
News
Robotic Breakthrough in Brain Surgery
Posted on
News
Bangladesh Achieves Remarkable Reduction in Lead in Turmeric
Posted on
News
Suppressing Negative Thoughts Can Improve Mental Health
Schizoaffective disorder is a chronic mental health condition characterized by the symptoms of schizophrenia, such as visual or auditory hallucinations, delusions, self-harm, impulsivity, and emotional dysregulation.
Patients affected with this disorder are often misdiagnosed with bipolar disorder or Schizophrenia. Schizoaffective disorder is less studied, and treatment interventions are often referred to for these disorders.
Schizoaffective disorder is rare, with an estimated lifetime prevalence rate of 0.3%. Men and women are affected by this disorder at the same rate. According to recent evidence, cases of this disorder develop between the age of 25 and 35.
Inpatient admissions of schizoaffective disorder are due to psychosis and are estimated to be about 10% to 30%. There are no large-scale studies on the epidemiology, incidence, and prevalence of the schizoaffective disorder.
The specific pathophysiology of schizoaffective disorder is unknown. Some studies suggest abnormalities of serotonin, dopamine and norepinephrine have a role.
White matter alterations in several brain areas, including the left temporal gyrus, right lentiform nucleus, and right precuneus, have also been linked to schizoaffective disorder and schizophrenia.
Researchers discovered diminished hippocampus volume and deformations of the medial and lateral thalamic regions in schizoaffective disorder patients.
There have been no definitive studies on the disorder’s cause. According to various research, up to 50% of individuals with schizophrenia have comorbid depression.
Both mood disorders and schizophrenia have heterogeneous pathogenesis that includes a variety of risk factors such as genetics, social factors, trauma, and stress. Stressful events and trauma usually trigger the disorder’s symptoms or onset.
To differentiate schizophrenia and schizoaffective disorder, an individual should have only psychomotor symptoms such as auditory or visual hallucinations for at least two weeks.
First-degree relatives have a higher risk of developing schizoaffective disorder. Individuals with a family history of bipolar disorder and schizophrenia are also at a higher risk of being affected.
Since the diagnostic criteria for schizoaffective disorder change periodically, prognosis studies have been challenging to conduct.
The estimated prognosis in individuals with psychotic disorder is about 50%. Schizoaffective disorder has various consequences on social functioning and daily activities if left untreated, like unemployment, depression, and reduced ability to care for self.
The prime reason for mortality is suicide; about 5% of patients with schizoaffective disorder commit suicide.
https://www.ncbi.nlm.nih.gov/books/NBK541012/
medtigo
Schizoaffective Disorder
Updated :
August 22, 2023
Schizoaffective disorder is a chronic mental health condition characterized by the symptoms of schizophrenia, such as visual or auditory hallucinations, delusions, self-harm, impulsivity, and emotional dysregulation.
Patients affected with this disorder are often misdiagnosed with bipolar disorder or Schizophrenia. Schizoaffective disorder is less studied, and treatment interventions are often referred to for these disorders.
Schizoaffective disorder is rare, with an estimated lifetime prevalence rate of 0.3%. Men and women are affected by this disorder at the same rate. According to recent evidence, cases of this disorder develop between the age of 25 and 35.
Inpatient admissions of schizoaffective disorder are due to psychosis and are estimated to be about 10% to 30%. There are no large-scale studies on the epidemiology, incidence, and prevalence of the schizoaffective disorder.
The specific pathophysiology of schizoaffective disorder is unknown. Some studies suggest abnormalities of serotonin, dopamine and norepinephrine have a role.
White matter alterations in several brain areas, including the left temporal gyrus, right lentiform nucleus, and right precuneus, have also been linked to schizoaffective disorder and schizophrenia.
Researchers discovered diminished hippocampus volume and deformations of the medial and lateral thalamic regions in schizoaffective disorder patients.
There have been no definitive studies on the disorder’s cause. According to various research, up to 50% of individuals with schizophrenia have comorbid depression.
Both mood disorders and schizophrenia have heterogeneous pathogenesis that includes a variety of risk factors such as genetics, social factors, trauma, and stress. Stressful events and trauma usually trigger the disorder’s symptoms or onset.
To differentiate schizophrenia and schizoaffective disorder, an individual should have only psychomotor symptoms such as auditory or visual hallucinations for at least two weeks.
First-degree relatives have a higher risk of developing schizoaffective disorder. Individuals with a family history of bipolar disorder and schizophrenia are also at a higher risk of being affected.
Since the diagnostic criteria for schizoaffective disorder change periodically, prognosis studies have been challenging to conduct.
The estimated prognosis in individuals with psychotic disorder is about 50%. Schizoaffective disorder has various consequences on social functioning and daily activities if left untreated, like unemployment, depression, and reduced ability to care for self.
The prime reason for mortality is suicide; about 5% of patients with schizoaffective disorder commit suicide.
https://www.ncbi.nlm.nih.gov/books/NBK541012/
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
